{"prompt": "['2016N277425_03', 'CONFIDENTIAL', '2018N377698_00', '201749', 'Spirometry for IC determination done in conjunction with FEV1 and FVC assessments', 'that is not obtained as follows will be considered a protocol deviation:', 'Started between 6:00AM and 11:00AM.', 'After withholding albuterol/salbutamol (all visits) >4 hours', 'At Visit 2 after discontinuation of run-in LABA or LAMA COPD medication and', 'prior to administration of study medication', 'At Visit 3, 4 and 5 after withholding the morning dose of study drug', '7.3.4.', 'COPD Exacerbation', 'A mild exacerbation is defined as worsening of symptoms that require no treatment with', 'antibiotics or steroids, and is self managed by the patient by an increase of inhaled rescue', 'medications. A moderate COPD exacerbation is defined as worsening symptoms of', 'COPD that require treatment with oral/systemic corticosteroids and/or antibiotics. A', 'severe exacerbation is defined as worsening symptoms of COPD that require in-patient', 'hospitalization or emergency room for longer than 24 hrs.', 'If a subject experiences a mild, moderate or severe COPD exacerbation, the COPD', 'exacerbation page of the eCRF should be completed. COPD exacerbations should not be', 'recorded as an AE, unless they meet the definition of a SAE. Details of COPD', 'exacerbation identification, categorization and treatment guidelines are described in', 'Appendix 5.', 'Subjects who experience a mild exacerbation during the run-in period will not be', 'withdrawn from the study. However, subjects who experience moderate or severe', 'exacerbation during the run-in period will be withdrawn from the study and will not be', 'allowed to be re-screened.', 'Subjects, who experience a mild, moderate or severe exacerbation during the treatment', 'period, will not be withdrawn from the study unless the investigator or GSK medical', 'monitor thinks it is best for the patient to withdraw from the study.', 'Signs and symptoms of COPD included on the electronic diary cards will not be', 'considered AEs and will not be recorded in the eCRF.', 'The time period for collection of COPD exacerbations will be from the Pre-Screening', '(Visit 0) until completion of the follow-up contact. If a subject experiences a COPD', 'exacerbation from the time the ICF is signed until randomization, summary information', '(yes/no status question) will be collected in the eCRF. COPD exacerbations after', 'randomization through follow-up will be recorded on the COPD exacerbation page of the', 'eCRF.', '7.3.5.', 'Clinically important deterioration (CID)', 'Clinically important deterioration (CID) is a composite endpoint defined as:', '53']['2016N277425_03', 'CONFIDENTIAL', '2018N377698_00', '201749', 'A decrease of 100 mL from baseline in trough FEV1', 'A deterioration in HRQoL defined as > 4 units increase from baseline in', 'SGRQ', 'The occurrence of an on-treatment moderate/severe COPD exacerbation', 'In addition, this study will explore CAT and TDI PROs as part of the composite', 'endpoint.', '7.3.6.', 'Rescue albuterol/salbutamol use', 'Subjects will record the number of daily albuterol/salbutemol puffs they use in the', 'eDiary. In addition, in some countries and selected sites the number of puffs will be', 'collected through the eMDI device (Section 6.2)', '7.3.7.', 'Physical activity monitor (study subset)', 'Physical activity limitation is a common feature of COPD and its measures are highly', 'related to the degree of disease severity [Watz, 2009].', 'Reduced physical activity levels in COPD is associated with increased morbidity and', 'mortality, sustained disability, depression, and social and physical isolation [Shu-Yi,', '2014; Gimeno, 2014]', 'Improved activity has been identified as an important factor that may modify morbidity', 'and mortality in COPD [Moy, 2012].', 'The Actigraph GT9X physical activity monitor will be used to measure levels of activity.', 'The activity monitor will be worn by up to approximately 150 subjects per treatment arm', 'for 7 days from Screening (Visit 1), for 7 days from Randomisation (Visit 2), 7 days from', 'Visit 3 (Week 4) and for 7 days prior to Week 24 (Visit 5).', 'There will be 4 assessment periods, including a screening assessment in order to provide', 'a reliable estimate of habitual physical activity. Each subject will be given an activity', 'monitor and instruction leaflet at the start of each assessment period. Further details of', 'distribution, operation and retrieval of the monitors will be provided in the SRM.', '7.4.', 'Safety', 'Planned time points for all safety assessments are listed in the Time and Events Table', '(Section 7.1)', 'Safety endpoint includes:', 'Incidence of adverse events', '7.4.1.', 'Adverse Events (AE) and Serious Adverse Events (SAEs)', 'The definitions of an AE or SAE can be found in Appendix 4.', '54']\n\n###\n\n", "completion": "END"}